Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heike Reinhardt

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Haematologica|August 2, 2016
Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scoresMonika Engelhardt, Sandra Maria Dold, Gabriele Ihorst, et al.
Cancers|September 10, 2021
Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related FactorsLaura Gengenbach, Giulia Graziani, Heike Reinhardt, et al.
Clinical and Experimental Nephrology|August 22, 2018
GFR estimation in lenalidomide treatment of multiple myeloma patients: a prospective cohort studyAndrea Schmidts, Julian Grünewald, Martina Kleber, et al.
Haematologica|July 11, 2015
Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 yearsMonika Engelhardt, Gabriele Ihorst, Ola Landgren, et al.
Leukemia & Lymphoma|March 24, 2018
Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials<sup/>Laura Gengenbach, Heike Reinhardt, Gabriele Ihorst, et al.
Cancer|January 30, 2019
Avoiding chemotherapy prescribing errors: Analysis and innovative strategiesHeike Reinhardt, Petra Otte, Alison G Eggleton, et al.
Haematologica|November 3, 2022
An objective assessment in newly diagnosed multiple myeloma to avoid treatment complications and strengthen therapy adherenceMaximilian Holler, Gabriele Ihorst, Heike Reinhardt, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 14, 2017
Paving the Way for Dose Banding of Chemotherapy: An Analytical ApproachHeike Reinhardt, Rainer Trittler, Alison G Eggleton, et al.
Haematologica|February 4, 2017
A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patientsMonika Engelhardt, Anne-Saskia Domm, Sandra Maria Dold, et al.
Annals of Hematology|June 5, 2025
Ixazomib-lenalidomid-dexamethasone (IRd) in relapsed refractory multiple myeloma (RRMM)-multicenter real-world analysis from Germany and comparative review of the literatureHanna Löffler, Magdalena Braun, Heike Reinhardt, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Haematologica|August 2, 2016
Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scoresMonika Engelhardt, Sandra Maria Dold, Gabriele Ihorst, et al.
Cancers|September 10, 2021
Choosing the Right Therapy for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Consideration of Patient-, Disease- and Treatment-Related FactorsLaura Gengenbach, Giulia Graziani, Heike Reinhardt, et al.
Clinical and Experimental Nephrology|August 22, 2018
GFR estimation in lenalidomide treatment of multiple myeloma patients: a prospective cohort studyAndrea Schmidts, Julian Grünewald, Martina Kleber, et al.
Haematologica|July 11, 2015
Large registry analysis to accurately define second malignancy rates and risks in a well-characterized cohort of 744 consecutive multiple myeloma patients followed-up for 25 yearsMonika Engelhardt, Gabriele Ihorst, Ola Landgren, et al.
Leukemia & Lymphoma|March 24, 2018
Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials<sup/>Laura Gengenbach, Heike Reinhardt, Gabriele Ihorst, et al.
Cancer|January 30, 2019
Avoiding chemotherapy prescribing errors: Analysis and innovative strategiesHeike Reinhardt, Petra Otte, Alison G Eggleton, et al.
Haematologica|November 3, 2022
An objective assessment in newly diagnosed multiple myeloma to avoid treatment complications and strengthen therapy adherenceMaximilian Holler, Gabriele Ihorst, Heike Reinhardt, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 14, 2017
Paving the Way for Dose Banding of Chemotherapy: An Analytical ApproachHeike Reinhardt, Rainer Trittler, Alison G Eggleton, et al.
Haematologica|February 4, 2017
A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patientsMonika Engelhardt, Anne-Saskia Domm, Sandra Maria Dold, et al.
Annals of Hematology|June 5, 2025
Ixazomib-lenalidomid-dexamethasone (IRd) in relapsed refractory multiple myeloma (RRMM)-multicenter real-world analysis from Germany and comparative review of the literatureHanna Löffler, Magdalena Braun, Heike Reinhardt, et al.
Pageof 2